IL4R and conjunctivitis: Given wide confidence intervals (e.g., dupilumab’s AE ARD spanning the null value), clinical decisions should be balanced against the biological plausibility of mechanism-related risks (e.g., IL-4Rα inhibition and conjunctivitis) and patient-specific factors (e.g., cardiorenal status).